JP2024500250A - Ｃｏｖｉｄ－１９の治療のためのｄｓｇ２組成物及び方法 - Google Patents

Ｃｏｖｉｄ－１９の治療のためのｄｓｇ２組成物及び方法 Download PDF

Info

Publication number
JP2024500250A
JP2024500250A JP2023560254A JP2023560254A JP2024500250A JP 2024500250 A JP2024500250 A JP 2024500250A JP 2023560254 A JP2023560254 A JP 2023560254A JP 2023560254 A JP2023560254 A JP 2023560254A JP 2024500250 A JP2024500250 A JP 2024500250A
Authority
JP
Japan
Prior art keywords
dsg2
isolated polypeptide
covid
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500250A5 (enExample
Inventor
イン フー、シー
エドワード タイラー、ライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvada Therapeutics Inc
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of JP2024500250A publication Critical patent/JP2024500250A/ja
Publication of JP2024500250A5 publication Critical patent/JP2024500250A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023560254A 2020-12-15 2021-12-15 Ｃｏｖｉｄ－１９の治療のためのｄｓｇ２組成物及び方法 Pending JP2024500250A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US63/125,583 2020-12-15
US202163274715P 2021-11-02 2021-11-02
US63/274,715 2021-11-02
PCT/US2021/063433 WO2022132854A1 (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Publications (2)

Publication Number Publication Date
JP2024500250A true JP2024500250A (ja) 2024-01-05
JP2024500250A5 JP2024500250A5 (enExample) 2024-11-29

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560254A Pending JP2024500250A (ja) 2020-12-15 2021-12-15 Ｃｏｖｉｄ－１９の治療のためのｄｓｇ２組成物及び方法

Country Status (9)

Country Link
EP (1) EP4263588A1 (enExample)
JP (1) JP2024500250A (enExample)
KR (1) KR20230120141A (enExample)
AU (1) AU2021400845A1 (enExample)
CA (1) CA3202364A1 (enExample)
IL (1) IL303444A (enExample)
MX (1) MX2023006704A (enExample)
TW (1) TW202237634A (enExample)
WO (1) WO2022132854A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005327A (es) * 2021-11-02 2024-05-21 Arvada Therapeutics Inc Composiciones y metodos de dsg2.
CN116458893A (zh) * 2023-04-19 2023-07-21 电子科技大学 一种covid-19后心肌缺血的早期筛查方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190353652A1 (en) * 2017-01-13 2019-11-21 The Hospital For Sick Children Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190353652A1 (en) * 2017-01-13 2019-11-21 The Hospital For Sick Children Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Fusion protein linkers: Property, design and functionality", ADVANCED DRUG DELIVERY REVIEWS, vol. 65, JPN6025041653, 2012, pages 1357 - 1369, ISSN: 0005818127 *

Also Published As

Publication number Publication date
AU2021400845A1 (en) 2023-07-13
CA3202364A1 (en) 2022-06-23
EP4263588A1 (en) 2023-10-25
WO2022132854A1 (en) 2022-06-23
TW202237634A (zh) 2022-10-01
MX2023006704A (es) 2023-06-20
KR20230120141A (ko) 2023-08-16
IL303444A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
KR20150121715A (ko) Ｃｓｆ１ 치료제
EA005005B1 (ru) ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
EA013470B1 (ru) Терапевтические агенты на основе токсичных пептидов
EA009938B1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
US10034915B2 (en) Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
CN111423502A (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
CA3202364A1 (en) Dsg2 compositions and methods for the treatment of covid-19
US20240279304A1 (en) Dsg2 compositions and methods
CN109328069A (zh) Il-22在治疗坏死性小肠结肠炎中的用途
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
JP6416480B2 (ja) 関節リウマチまたはその関連疾患の予防または治療剤
JP4599028B2 (ja) 新規な炎症性疾患改善剤
CN119874872B (zh) 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用
US20190358307A1 (en) Therapeutic agent for cerebral infarction
JP5439007B2 (ja) 血管内皮細胞増殖因子阻害剤及び抗癌剤
WO2022020544A1 (en) Method of treating an inflammatory condition
HK1223556B (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
HK40002973B (en) An il-22 dimer for use in treating necrotizing enterocolitis
HK40002973A (en) An il-22 dimer for use in treating necrotizing enterocolitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260609